PMO Revenue and Competitors

PMO is a startup cannabinoid biotech focused on CB2/ECS research and product development. We are extracting (ECS/CB2-specific agonists) cannabinoids from plants that are NOT cannabis or hemp to create formulations that have similar health benefits and effects. Because none of our products contain cannabis and therefore THC, our products can support your health in the same way as cannabis can, but without the psychoactive effects. Plus: 99% less cost compared to CBD/cannabis products, and otc-legal worldwide today. "The recent discovery of different plants with compounds that modulate the Endocannabinoid System (ECS) means we can no longer simply define plant cannabinoids as merely a product of cannabis/hemp." -Roger Pertwee, GW Pharmaceuticals "Changes in endocannabinoid levels and/or CB2 receptor expressions have been reported in almost ALL diseases affecting humans, ranging from cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, auto-immune, lung disorders to pain and cancer, and modulating CB2 receptor activity holds TREMENDOUS therapeutic potential in these pathologies." -Prof Raphael Mechoulam/Grandfather of Cannabinoid Research PMO Reseller benefits (active): 1) *Starter sample product (100% natural pharmaceutical-grade cannabinoids: 30,000 mg), 2) *50% discount on additional product, 3) One-time $15/unit commission to active resellers only. *s/h not included